Drug Search Results
More Filters [+]

VTP-300

Alternative Names: VTP-300, VTP300, VTP 300
Latest Update: 2024-01-08
Latest Update Note: News Article

Product Description

VTP-300 is an immunotherapeutic agent that Vaccitech intends to administer in combination with a low-dose anti-PD-1 antibody, to counterbalance the immune suppression and T cell exhaustion in the liver caused by CHB. (Sourced from: https://www.vaccitech.co.uk/pipeline/)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Arbutus Biopharma
Company Location: BURNABY A1 V5J 5J8
Company CEO: William Collier
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for VTP-300

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Hepatitis B, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACTRN12622000317796

P2

Recruiting

Hepatitis B, Chronic

2022-08-31

Recent News Events